Consensual therapeutic algorithm for type 2 diabetes mellitus (in accordance with SPC, ADA/EASD indicative limitations and recommendations )
Authors:
Emil Martinka 1; Vladimír Uličiansky 2; Marián Mokáň 3; Ivan Tkáč 4; Peter Galajda 3; Zbynek Schroner 5*
Authors‘ workplace:
Národný endokrinologický a diabetologický ústav n. o. v Ľubochni
1; Via medica, s. r. o., Košice
2; I. interná klinika Jesseniovej LF UK a UNM, Martin
3; IV. interna klinika UN L. Pasteura Košice a LF UPJŠ v Košiciach
4; SchronerMED, s. r. o., interná a diabetologická ambulancia, Košice
5
Published in:
Forum Diab 2016; 5(2): 99-108
Category:
Guidelines
*v spolupráci členov výboru Slovenskej diabetologickej spoločnosti
Overview
Type 2 diabetes mellitus is a heterogeneous medical condition involving multiple pathophysiological mechanisms. Its successful treatment requires an individualized approach and frequently combined therapy with utilizing its effect on multiple levels. Current possibilities enable the employment of such procedures to an incomparably greater extent than before. The effects of different classes of oral antidiabetic drugs on the reduction of glycemia and HbA 1c is mutually comparable. However differences are observed in the proportions of patients who met the required criteria, regarding the increase in weight, incidence of hypoglycemia as well as the effect on cardiovascular, renal or oncologic morbidity and mortality, and severity of specific adverse effects, potential risks and contraindications. The presented text provides the reader with the information about the Consensual therapeutic algorithm for the treatment of type 2 diabetes mellitus in compliance with SPC, the ADA/EASD amended indicative limitations and recommendations, formulated by the Committee of the Slovak Diabetes Society.
Key words:
agonisty GLP-1 receptor agonists – biguanides – gliflozins – gliptins – glitazones – insulin – sulfonylurea
Sources
1. Abrahamson MJ, Barzilay YI, Blonde L et al. Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract 2015; 21(4) e1. Dostupné z DOI: <http://dx.doi.org/10.4158/EP15693.CS>.
2. Gerstein HC, Miller ME, Byington RP et al. [Action to Control Cardiovascular Risk in Diabetes Study Group]. Effect of intensive glucose lowering in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559.
3. Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative Group]. Intensive Blood Glucose Control and VascularOutcomes in Patients with Type 2 Diabetes N Engl J Med 2008; 358(24): 2560–2572.
4. Bonds DE, MillerME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.b4909>.
5. Dormandy JA, Charbonnel B, Eckland DJA et al. [PROactive investigators]. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279–89.
6. Green JB., Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232–242.
7. Holden SE, Jenkins-Jones S, Morgan CL et al. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab 2015; 17(4): 350–362.
8. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589.
9. Aktuálne znenie indikačných obmedzení pre preskripciu liekov hradených z verejného poistenia. Dostupné z WWW: <http://www.health.gov.sk/Clanok?lieky201605>.
10. Inzucchi ES, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140–149.
11. Informácie dostupné z WWW: <http://www.medscape.com/viewarticle/859905>.
12. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48(5): 643–648.
13. Martinka E. NEFRITI. Dostupné z WWW: <http://dia.euni.sk/category/167-komplikacie-diabetes-mellitus/181-mikrovaskularne-komplikacie/article/2002-nefriti?bid=3>.
14. Martinka, E, Pontuch P, Mišániková M et al. Výskyt diabetickej nefropatie v populácii pacientov s diabetes mellitus na Slovenku : Výsledky prieskumu NEFRITI. Forum Diab 2015; 4(3): 198–207.
15. Mechanick JI, Marchetti AE, Apovian C et al. Diabetes-specific nutrition algorithm: a transcultural program to optimize diabetes and prediabetes care. Curr Diab Rep 2012; 12(2): 180–94.
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24):2457–2471. Erratum in N Engl J Med. 2007; 357(1): 100.
17. Gerstein HC, Bosch J, Dagenais GR et al. [Origin Trial Investigators]. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med, 2012; 367(4): 319–328.
18. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors. Diabetes Care 2015; 38(9): 1638–1642.
19. Scirica BM., Bhatt DL, Braunwald E et al. [SAVOR-TIMI 53 Steering Committee and Investigators]. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus N Engl J Med 2013; 369(4): 1317–1326.
20. Shah AD, Langenberg C, Rapsomaniki E et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1–9 million people. Lancet Diabetes Endocrinol 2015; 3(2): 105–113.
21. Schernthaner G, Curie CJ, Schernthaner GH. Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabets Care 2013; 36(Suppl 2): S155-S161.
22. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32(15): 1900–1908. Erratum in Eur Heart J 2012; 33(10): 1183.
23. [UK Prospective Diabetes Study (UKPDS) Group]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–853. Erratum inLancet 1999; 354(9178): 602.
24. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865. Erratum in: Lancet 1998; 352(9139): 1558.
25. Yki-Järvinen H, Bergenstal R, Ziemen M et al. [EDITION 2 Study Investigators]. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37(12): 3235–3243.
26. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128.
27. Zoungas S, Chalmers J, Neal B. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371(15): 1392–1406.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2016 Issue 2
Most read in this issue
- Consensual therapeutic algorithm for treatment with insulin pump and continuous monitoring of glucose levels (in compliance with the indicative limitations as amended)
- Consensual therapeutic algorithm for type 2 diabetes mellitus (in accordance with SPC, ADA/EASD indicative limitations and recommendations )
- Kidney transplantation and metabolic syndrome
- Iatrogenic hypoglycemia as a serious medical problem